2020 American Transplant Congress
Evaluation of Infectious and Malignant Complications in Elderly Renal Transplant Recipients Receiving Alemtuzumab Compared to Basiliximab
*Purpose: The choice of induction immunosuppression can affect several outcomes after kidney transplant (KTx), especially for elderly recipients. For this population, there is limited data…2020 American Transplant Congress
Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte Precursors (EBV-CTLp) after Tab-cel Correlates with Response & Survival in Rituximab Relapsing or Refractory Ebv+ Posttransplant Lymphoproliferative Disease (PTLD)
*Purpose: EBV+ PTLD is often a fatal disease. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approximated…2020 American Transplant Congress
Transplant Monitoring and PTLD Detection with B Cell Receptor Repertoire Analysis in a Large Prospective Pediatric Cohort
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is a…2020 American Transplant Congress
Outcomes of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders: An Analysis of the UNOS/OPTN Database (1998 to 2019)
*Purpose: Post-transplant lymphoproliferative disease (PTLD) is a serious, potentially fatal complication after kidney transplantation. Existing literature on outcomes of kidney retransplantation in patients with prior…2020 American Transplant Congress
Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database
1United Network for Organ Sharing (UNOS), Richmond, VA, 2Bristol-Myers Squibb, Princeton, NJ
*Purpose: Belatacept, a selective T-cell costimulation blocker, was approved in 2011 for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients. PTLD…2020 American Transplant Congress
Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study
*Purpose: There is a need for effective, well‑tolerated therapies in pts who develop Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ (SOT) or…2019 American Transplant Congress
Lower Rates of Epstein-Barr Virus Viremia and Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients Who Received Valganciclovir Prophylaxis
*Purpose: Antiviral prophylaxis to prevent post-transplant lymphoproliferative disease (PTLD) remains controversial, but some data suggest that valganciclovir or ganciclovir use in Epstein-Barr virus (EBV) high-risk…2019 American Transplant Congress
Regulation of Host microRNA Expression by Natural Variants of Epstein Barr Virus (EBV) Latent Membrane Protein 1 (LMP1)
*Purpose: Malignancies attributable to EBV, such as post-transplant lymphoproliferative disorder (PTLD), represent 1.8% of global cancer deaths. PTLD occurs in 1-20% of transplant recipients and…2019 American Transplant Congress
Mass Cytometry-Based Characterization of Adaptive Immunity in Transplant Recipients with Self-Limiting or Chronic EBV Viremia
1UHN, Toronto, ON, Canada, 2SickKids Research Inst, Toronto, ON, Canada
*Purpose: SOT recipients are at high risk for EBV-associated PTLD. EBV viremia is a risk factor for PTLD. In some patients viremia is self-limited while…2019 American Transplant Congress
Ex-Vivo Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) can manifest as a B-cell malignancy associated with Epstein-Barr virus (EBV) infection. Risk of PTLD is greatest in EBV D+/R-…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 9
- Next Page »